

## June 2022 Quarterly Update and Appendix 4C

### HIGHLIGHTS:

- **Strong cash balance of \$12,272,000 supporting multiple cancer programs**
- **Progress on multiple fronts as all programs advance to schedule**
- **PTX-200 and PTX-100 studies progress on encouraging clinical results**
- **New clinic-ready CellPryme-M platform for enhancing cell therapies developed with Peter MacCallum Cancer Centre Melbourne unveiled**

**MELBOURNE Australia, 25 July 2022** – Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing personalised therapies to treat cancer, today reported its June 2022 quarter results and operating highlights.

The Company is in a strong cash position with multiple cancer programs reporting favourable progress. The business is steadily advancing towards several value creating milestones.

### Financial update

Prescient ended the quarter with a cash balance of \$12.3 million. Costs for the quarter included ongoing clinical trials and manufacturing for PTX-100 and PTX-200 as well as the OmniCAR next-generation CAR-T platform and newly unveiled high-performance cell therapy manufacturing technology CellPryme-M.

Total cash outflows for the quarter were largely in line with the previous quarter at \$1.2 million, with \$0.5 million invested in research and development activities in Australia and the United States. Payments during the period to related parties of the entity and associates, were \$158,000. These payments relate to non-executive director fees as well as salary and superannuation for the CEO and Managing Director.

As noted previously, Prescient maintains close watch over operating costs and the management of its cash reserves to enable the business to continue to execute on multiple programs.

### Improving and advancing the efficacy of existing CAR-T therapies

An important strategic milestone during the reporting period was disclosure of Prescient's CellPryme-M, an advanced CAR-T cell manufacturing enhancement technology developed in collaboration with the world-leading Peter MacCallum Cancer Centre (Peter Mac) in Melbourne. This program has been in development for some time in stealth mode whilst data was generated and patents filed.

CellPryme-M complements Prescient's OmniCAR platform by solving some of the key problems facing current and emerging cell therapies.

For personal use only

In simple terms, CellPryme-M allows Prescient to manufacture superior cell products that make CAR-T treatments more clinically effective for the treatment of cancer. It was created to directly address a major clinical shortcoming of current CAR-T therapies.

More specifically, CellPryme-M produces more favourable cell phenotypes that are known to drive superior clinical outcomes, including:

- 50% more central memory T cells, a highly clinically relevant sub-type important for sustained tumour killing;
- Double proportion of CD4+ helper T cells, for synergy with effector T cells;
- Significantly more chemokine receptors, important for tumour trafficking and tumour penetrance, especially important in solid tumours; and
- Greater genomic stability and DNA repair for enhanced self-renewal.

CellPryme-M has wide application for enhancing not only Prescient's internal OmniCAR programs, but also current generation cell therapies. It requires minimal intervention into existing and emerging manufacturing process and therefore represents a relatively low implementation hurdle. This opens up real commercial opportunities for Prescient to incorporate CellPryme-M into third party manufacturing processes.

Moreover, CellPryme-M is ready for clinical testing, with GMP materials available to partners.

This significant milestone is testament to the ingenuity and relationship between teams at Prescient and the Peter Mac.

#### **PTX-100 expands study on promising results in T-cell lymphoma patients**

Patients with T-cell lymphomas (TCL) are being steadily enrolled and treated in the expansion cohort under the leadership of Professor Miles Prince, AM.

Prescient anticipates that recruitment remains on track for completion by the end of calendar 2022 and looks forward to sharing an interim update as the trial unfolds.

#### **PTX-200 study expands cohort after 4th complete remission**

In parallel, Prescient's Phase 1b study of PTX-200 combined with chemotherapy (cytarabine) in patients with relapsed and refractory acute myeloid leukemia (AML) reported that another patient in the study has now had complete remission of their disease at the 45mg/m<sup>2</sup> dose. An additional partial response was also previously reported. Four patients in the study have now reported complete remission of their disease.

Principal Investigator, Professor Jeffery Lancet, at the H. Lee Moffitt Cancer Center in Florida, together with Prescient, believes a dose level of 45mg/m<sup>2</sup> of PTX-200 is worth exploring as be the optimal biological dose for patients with this aggressive cancer. Prescient looks forward to providing an update on this cohort in the coming months.

#### **OmniCAR progress continues**

Although no results have been made public on the OmniCAR programs, the Company is pleased to report that steady progress has been made across its programs, including in vivo studies. Despite the



necessary optimisations required in therapeutic development, Prescient is pleased to report that data is unfolding that confirms its belief that OmniCAR is a transformative platform that can yield truly differentiated cell therapies.

The Company looks forward to updating the market on these developments whilst being sensitive to ongoing commercial disclosure limitations.

### **Solid progress on all fronts set to continue**

The Company thanks every shareholder for their ongoing support. The Board and management remain focused and confident in the Company's progress based on the positive outcomes of its clinical programs and continued solid technical advances made by its CAR-T CellPryme-M and OmniCAR programs.

The ongoing insights, advice and support of our highly regarded expert medical and clinical collaborators confirms that together, Prescient, and its team of collaborators, are collectively moving towards being able to deliver meaningful and significant improvements in the ability of doctors worldwide to treat patients with a range of hard-to-treat cancers.

The Appendix 4C - Quarterly Cash Flow Report for the June 2022 quarter is attached.

**- Ends -**

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.

### **About Prescient Therapeutics Limited (Prescient)**

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

### **Cell Therapies**

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

**CellPryme-M:** Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during



cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPrime-M.

### Targeted Therapies

**PTX-100** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it has shown encouraging efficacy signals and safety.

**PTX-200** is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound is currently in a Phase 1b/2 trial in relapsed and refractory AML, where it has resulted in 4 complete remissions so far. PTX-200 previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at [www.ptxtherapeutics.com](http://www.ptxtherapeutics.com) or connect with us via Twitter [@PTX\\_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

Steven Yatomi-Clarke

CEO & Managing Director

Prescient Therapeutics

[steven@ptxtherapeutics.com](mailto:steven@ptxtherapeutics.com)

**Investor enquiries:**

Sophie Bradley – Reach Markets

+61 450 423 331

[ir@reachmarkets.com.au](mailto:ir@reachmarkets.com.au)

**Media enquiries:**

Andrew Geddes – CityPR

+61 2 9267 4511

[ageddes@citypublicrelations.com.au](mailto:ageddes@citypublicrelations.com.au)

### Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-



looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward- looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

#### **Supplemental COVID-19 Risk Factors**

Please see our website: [Supplemental COVID-19 Risk Factors](#)

For personal use only

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Prescient Therapeutics Limited

**ABN**

56 006 569 106

**Quarter ended ("current quarter")**

30 June 2022

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(493)	(3,174)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(185)	(997)
(f) administration and corporate costs	(558)	(1,676)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	11	30
1.5 Interest and other costs of finance paid	-	(7)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	58	1,434
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(1,167)</b>	<b>(4,390)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	(4)	(4)
(j) investments	-	-
(k) intellectual property	-	-
(l) other non-current assets	-	-

For personal use only

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(4)</b>	<b>(4)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	264	568
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(3)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(83)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>264</b>	<b>482</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	13,129	16,097
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,167)	(4,390)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(4)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	264	482
4.5	Effect of movement in exchange rates on cash held	50	87
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>12,272</b>	<b>12,272</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	2,272	3,129
5.2	Call deposits	10,000	10,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>12,272</b>	<b>13,129</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	158
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*



7. <b>Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-
7.5 <b>Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,167)
8.2 Cash and cash equivalents at quarter end (item 4.6)	12,272
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	12,272
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	10.5
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: N/A	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 25 July 2022

Authorised by: By the Board

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.